Skip to content

Clinical trials

Phase 4 Diabetes Mellitus, Type 2 trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus, Type 2 Phase: Phase 4 Clear all

1,183 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20004
200111
200228
200339
200433
200540
200635
200743
200859
200968
201060
201151
201253
201363
201474
201574
201673
201746
201845
201940
202032
202139
202230
202328
202438
202533
202628

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed803
Unknown status167
Terminated84
Recruiting53
Withdrawn30
Not yet recruiting23
Active, not recruiting16
Enrolling by invitation4
Suspended3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S75
Sanofi75
Eli Lilly and Company33
AstraZeneca28
GlaxoSmithKline23
Novartis Pharmaceuticals22
Emory University15
Seoul National University Bundang Hospital15
Takeda13
The University of Texas Health Science Center at San Antonio13

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus, Type 21,183
Diabetes Mellitus250
Insulin Resistance76
Obesity60
Hypertension55
Coronary Artery Disease43
Cardiovascular Diseases31
Hyperglycemia27
Dyslipidemias25
Atherosclerosis23

Trials

Showing 1 to 25 of 1,183. Each trial links to its page on Pharma Observatory.

1,083 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.